IL-15 signaling in NK cell cancer immunotherapy

Current Opinion in Immunology

Volumn 44, Issue , 2017, Pages 1-6

  Rautela, Jai ^a,b   Huntington, Nicholas D ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANZYME B; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; JANUS KINASE 1; JANUS KINASE 3; PERFORIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN SH2; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR IDB2; TRANSCRIPTION FACTOR NFIL3; UNCLASSIFIED DRUG; CANCER VACCINE;

CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELL; GENE DELETION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOREACTIVITY; IMMUNOREGULATION; INNATE IMMUNITY; KERATINOCYTE; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CYTOTOXICITY; IMMUNOLOGY; METABOLISM; NEOPLASM; PROCEDURES; TRANSPLANTATION;

ANIMALS; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; KILLER CELLS, NATURAL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84994560080     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.10.004     Document Type: Review

References (59)

1. 1 Sun, J.C., Lanier, L.L., NK cell development, homeostasis and function: parallels with CD8(+) T cells. Nat Rev Immunol 11 (2011), 645–657.
2. 2 Waldmann, T.A., Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol 10 (2014), 1689–1701.
3. 3 Kiessling, R., Klein, E., Wigzell, H., ‘Natural’ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 5 (1975), 112–117.
4. 4 Kiessling, R., Klein, E., Pross, H., Wigzell, H., “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 5 (1975), 117–121.
5. 5 Pross, H.F., Jondal, M., Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes. Clin Exp Immunol 21 (1975), 226–235.
6. 6 Herberman, R.B., Nunn, M.E., Holden, H.T., Lavrin, D.H., Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 16 (1975), 230–239.
7. 7 Herberman, R.B., Nunn, M.E., Lavrin, D.H., Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 16 (1975), 216–229.
8. 8• Seillet, C., Huntington, N.D., Gangatirkar, P., Axelsson, E., Minnich, M., Brady, H.J., Busslinger, M., Smyth, M.J., Belz, G.T., Carotta, S., Differential requirement for Nfil3 during NK cell development. J Immunol 192 (2014), 2667–2676 Identification that Nfil3 is critical for NK cell but not ILC1 development in the liver of mice.
9. 9•• Delconte, R.B., Shi, W., Sathe, P., Ushiki, T., Seillet, C., Minnich, M., Kolesnik, T.B., Rankin, L.C., Mielke, L.A., Zhang, J.G., et al. The helix–loop–helix protein ID2 governs NK cell fate by tuning their sensitivity to interleukin-15. Immunity 44 (2016), 103–115 These data identify the mechanistic requirement for ID2 in NK cell homeostasis. ID2 is constantly required to suppress E2A-target genes and maintain optimal IL-15 signaling.
10. 10 Seillet, C., Belz, G.T., Huntington, N.D., Development, homeostasis, and heterogeneity of NK cells and ILC1. Curr Top Microbiol Immunol 395 (2016), 37–61.
11. 11 Yokota, Y., Mansouri, A., Mori, S., Sugawara, S., Adachi, S., Nishikawa, S., Gruss, P., Development of peripheral lymphoid organs and natural killer cells depends on the helix–loop–helix inhibitor Id2. Nature 397 (1999), 702–706.
12. 12 Gascoyne, D.M., Long, E., Veiga-Fernandes, H., de Boer, J., Williams, O., Seddon, B., Coles, M., Kioussis, D., Brady, H.J., The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol 10 (2009), 1118–1124.
13. 13 Carotta, S., Pang, S.H., Nutt, S.L., Belz, G.T., Identification of the earliest NK-cell precursor in the mouse BM. Blood 117 (2011), 5449–5452.
14. 14 Kallies, A., Carotta, S., Huntington, N.D., Bernard, N.J., Tarlinton, D.M., Smyth, M.J., Nutt, S.L., A role for Blimp1 in the transcriptional network controlling natural killer cell maturation. Blood 117 (2011), 1869–1879.
15. 15• Holmes, M.L., Huntington, N.D., Thong, R.P., Brady, J., Hayakawa, Y., Andoniou, C.E., Fleming, P., Shi, W., Smyth, G.K., Degli-Esposti, M.A., et al. Peripheral natural killer cell maturation depends on the transcription factor Aiolos. EMBO J 33 (2014), 2721–2734 These two papers identify transcription factors critical for the differentiation and effector function of NK cells. Ikzf3 is required for the terminal NK cell differentiation whereas Zeb2, like Tbx21 is required for entry into the mature NK cell pool.
16. •].
17. 17 Burkett, P.R., Koka, R., Chien, M., Chai, S., Boone, D.L., Ma, A., Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med 200 (2004), 825–834.
18. 18 Schluns, K.S., Nowak, E.C., Cabrera-Hernandez, A., Puddington, L., Lefrancois, L., Aguila, H.L., Distinct cell types control lymphoid subset development by means of IL-15 and IL-15 receptor alpha expression. Proc Natl Acad Sci U S A 101 (2004), 5616–5621.
19. 19 Lodolce, J.P., Burkett, P.R., Boone, D.L., Chien, M., Ma, A., T cell-independent interleukin 15Ralpha signals are required for bystander proliferation. J Exp Med 194 (2001), 1187–1194.
20. 20 Bergamaschi, C., Bear, J., Rosati, M., Beach, R.K., Alicea, C., Sowder, R., Chertova, E., Rosenberg, S.A., Felber, B.K., Pavlakis, G.N., Circulating IL-15 exists as heterodimeric complex with soluble IL-15Ralpha in human and mouse serum. Blood 120 (2012), e1–e8.
21. 21 Huntington, N.D., The unconventional expression of IL-15 and its role in NK cell homeostasis. Immunol Cell Biol 92 (2014), 210–213.
22. 22 Dubois, S., Mariner, J., Waldmann, T.A., Tagaya, Y., IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17 (2002), 537–547.
23. 23 Cooper, M.A., Bush, J.E., Fehniger, T.A., VanDeusen, J.B., Waite, R.E., Liu, Y., Aguila, H.L., Caligiuri, M.A., In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100 (2002), 3633–3638.
24. 24 Koka, R., Burkett, P.R., Chien, M., Chai, S., Chan, F., Lodolce, J.P., Boone, D.L., Ma, A., Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice. J Exp Med 197 (2003), 977–984.
25. 25 Sandau, M.M., Schluns, K.S., Lefrancois, L., Jameson, S.C., Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15R alpha by the same cells. J Immunol 173 (2004), 6537–6541.
26. 26 Kennedy, M.K., Glaccum, M., Brown, S.N., Butz, E.A., Viney, J.L., Embers, M., Matsuki, N., Charrier, K., Sedger, L., Willis, C.R., et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191 (2000), 771–780.
27. 27 Castillo, E.F., Acero, L.F., Stonier, S.W., Zhou, D., Schluns, K.S., Thymic and peripheral microenvironments differentially mediate development and maturation of iNKT cells by IL-15 transpresentation. Blood 116 (2010), 2494–2503.
28. 28 Waldmann, T.A., Tagaya, Y., The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 17 (1999), 19–49.
29. 29 Giri, J.G., Kumaki, S., Ahdieh, M., Friend, D.J., Loomis, A., Shanebeck, K., DuBose, R., Cosman, D., Park, L.S., Anderson, D.M., Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J 14 (1995), 3654–3663.
30. 30 Giri, J.G., Ahdieh, M., Eisenman, J., Shanebeck, K., Grabstein, K., Kumaki, S., Namen, A., Park, L.S., Cosman, D., Anderson, D., Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13 (1994), 2822–2830.
31. 31 Colpitts, S.L., Stoklasek, T.A., Plumlee, C.R., Obar, J.J., Guo, C., Lefrancois, L., Cutting edge: the role of IFN-alpha receptor and MyD88 signaling in induction of IL-15 expression in vivo. J Immunol 188 (2012), 2483–2487.
32. 32 Colpitts, S.L., Stonier, S.W., Stoklasek, T.A., Root, S.H., Aguila, H.L., Schluns, K.S., Lefrancois, L., Transcriptional regulation of IL-15 expression during hematopoiesis. J Immunol 191 (2013), 3017–3024.
33. 33 Mortier, E., Woo, T., Advincula, R., Gozalo, S., Ma, A., IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 205 (2008), 1213–1225.
34. 34 Wang, X., Lupardus, P., Laporte, S.L., Garcia, K.C., Structural biology of shared cytokine receptors. Annu Rev Immunol 27 (2009), 29–60.
35. 35 Imada, K., Leonard, W.J., The Jak-STAT pathway. Mol Immunol 37 (2000), 1–11.
36. 36• Sathe, P., Delconte, R.B., Souza-Fonseca-Guimaraes, F., Seillet, C., Chopin, M., Vandenberg, C.J., Rankin, L.C., Mielke, L.A., Vikstrom, I., Kolesnik, T.B., et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat Commun, 5, 2014, 4539 Conclusive evidence that the STAT5-target gene Mcl1, is essential for NK cell survival. This finding allowed the authors to generate a specific NK cell null mouse for cancer studies.
37. 37•• Marcais, A., Cherfils-Vicini, J., Viant, C., Degouve, S., Viel, S., Fenis, A., Rabilloud, J., Mayol, K., Tavares, A., Bienvenu, J., et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol 15 (2014), 749–757 Elegant and detailed study into the role of the mTOR pathway in NK cell metabolism in mice. mTOR signaling was essential for NK cell development and differentiation in vivo and its activity was governed by IL-15.
38. 38 Babon, J.J., Kershaw, N.J., Murphy, J.M., Varghese, L.N., Laktyushin, A., Young, S.N., Lucet, I.S., Norton, R.S., Nicola, N.A., Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36 (2012), 239–250.
39. 39 Zhang, J., Siraganian, R.P., CD45 is essential for Fc epsilon RI signaling by ZAP70, but not Syk, in Syk-negative mast cells. J Immunol 163 (1999), 2508–2516.
40. 40 Zawislak, C.L., Beaulieu, A.M., Loeb, G.B., Karo, J., Canner, D., Bezman, N.A., Lanier, L.L., Rudensky, A.Y., Sun, J.C., Stage-specific regulation of natural killer cell homeostasis and response against viral infection by microRNA-155. Proc Natl Acad Sci U S A 110 (2013), 6967–6972.
41. 41 Dudda, J.C., Salaun, B., Ji, Y., Palmer, D.C., Monnot, G.C., Merck, E., Boudousquie, C., Utzschneider, D.T., Escobar, T.M., Perret, R., et al. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 38 (2013), 742–753.
42. 42 Rosenberg, S.A., IL-2: the first effective immunotherapy for human cancer. J Immunol 192 (2014), 5451–5458.
43. 43 Ahmadzadeh, M., Rosenberg, S.A., IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107 (2006), 2409–2414.
44. 44 Cesana, G.C., DeRaffele, G., Cohen, S., Moroziewicz, D., Mitcham, J., Stoutenburg, J., Cheung, K., Hesdorffer, C., Kim-Schulze, S., Kaufman, H.L., Characterization of CD4 + CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24 (2006), 1169–1177.
45. 45 Waldmann, T.A., The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res 3 (2015), 219–227.
46. 46 Rubinstein, M.P., Kovar, M., Purton, J.F., Cho, J.H., Boyman, O., Surh, C.D., Sprent, J., Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A 103 (2006), 9166–9171.
47. 47 Huntington, N.D., Legrand, N., Alves, N.L., Jaron, B., Weijer, K., Plet, A., Corcuff, E., Mortier, E., Jacques, Y., Spits, H., et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 206 (2009), 25–34.
48. 48 Mortier, E., Quemener, A., Vusio, P., Lorenzen, I., Boublik, Y., Grotzinger, J., Plet, A., Jacques, Y., Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 × IL-15R alpha fusion proteins. J Biol Chem 281 (2006), 1612–1619.
49. 49 Bessard, A., Sole, V., Bouchaud, G., Quemener, A., Jacques, Y., High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 8 (2009), 2736–2745.
50. 50 Rhode, P.R., Egan, J.O., Xu, W., Hong, H., Webb, G.M., Chen, X., Liu, B., Zhu, X., Wen, J., You, L., et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res 4 (2016), 49–60.
51. 51 Rosario, M., Liu, B., Kong, L., Collins, L.I., Schneider, S.E., Chen, X., Han, K., Jeng, E.K., Rhode, P.R., Leong, J.W., et al. The IL-15-based ALT-803 complex enhances FcgammaRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clin Cancer Res 22 (2016), 596–608.
52. 52 Mathios, D., Park, C.K., Marcus, W.D., Alter, S., Rhode, P.R., Jeng, E.K., Wong, H.C., Pardoll, D.M., Lim, M., Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int J Cancer 138 (2016), 187–194.
53. 53 Boyman, O., Kovar, M., Rubinstein, M.P., Surh, C.D., Sprent, J., Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311 (2006), 1924–1927.
54. 54 Guo, Y., Luan, L., Rabacal, W., Bohannon, J.K., Fensterheim, B.A., Hernandez, A., Sherwood, E.R., IL-15 superagonist-mediated immunotoxicity: role of NK cells and IFN-gamma. J Immunol 195 (2015), 2353–2364.
55. 55 Yoshimura, A., Ohkubo, T., Kiguchi, T., Jenkins, N.A., Gilbert, D.J., Copeland, N.G., Hara, T., Miyajima, A., A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. Embo J 14 (1995), 2816–2826.
56. 56 Matsumoto, A., Masuhara, M., Mitsui, K., Yokouchi, M., Ohtsubo, M., Misawa, H., Miyajima, A., Yoshimura, A., CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89 (1997), 3148–3154.
57. 57 Aman, M.J., Migone, T.S., Sasaki, A., Ascherman, D.P., Zhu, M., Soldaini, E., Imada, K., Miyajima, A., Yoshimura, A., Leonard, W.J., CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling. J Biol Chem 274 (1999), 30266–30272.
58. 58•• Delconte, R.B., Kolesnik, T.B., Dagley, L.F., Rautela, J., Shi, W., Putz, E.M., Stannard, K., Zhang, J.G., Teh, C., Firth, M., et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat Immunol 17 (2016), 816–824 Breakthrough in our understanding of IL-15 regulation in NK cells. Deletion of the SOCS protein CIS resulted in hyperactive JAK1 in NK cells and prevented tumor metastasis in mice.
59. 59• Bottos, A., Gotthardt, D., Gill, J.W., Gattelli, A., Frei, A., Tzankov, A., Sexl, V., Wodnar-Filipowicz, A., Hynes, N.E., Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nat Commun, 7, 2016, 12258 While investigating the therapeutic benefit of JAK1 inhibition in a breast cancer model, the authors found that treatment resulted in more metastasis due to impaired NK cell survival. JAK1 activity is thus key to NK cell fitness.